Source: U.S Food and Drug Administration
Date of publication: August 2009
Publication type: News
In a nutshell: The FDA has announced it is carrying out a review of Orlistat (Alli), the obesity management drug after several reports that it caused liver injury. No direct link has been found between Orlistat and kidney injury, but the FDA urges users and healthcare professionals to report side effects using the Adverse Event Report programme. The results of the review will be announced at a later date.
Length of publication: 1 page